DiaMedica Therapeutics Inc Sustainability Reports

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious vascular and neurological diseases. Its lead candidate, DM199, is a recombinant form of the human tissue kallikrein-1 protein being investigated for acute ischemic stroke and preeclampsia.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

FIGI: BBG001SQ3K65

6 reports from 2016 to 2025

• DiaMedica Therapeutics Inc 2025 Annual Report and Annual General Meeting Proxy Statement
• DiaMedica Therapeutics Inc 2023 Annual Report & Annual General Meeting Proxy Statement
• DiaMedica Therapeutics Inc 2019 Annual Report
• DiaMedica Therapeutics Inc 2018 Annual Report
• DiaMedica Therapeutics Inc 2017 Consolidated Financial Statements